Status:
UNKNOWN
Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs
Lead Sponsor:
Rambam Health Care Campus
Conditions:
NIDDM
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
This feasibility study is designed to examine modulation of the relative activities of ACE and ACE2 in diabetic patients following treatment with the angiotensin type 1 receptor (AT1R) antagonist, Can...
Eligibility Criteria
Inclusion
- Signed informed consent
- Non-smokers
- Type II DM diagnosed patients
- Blood pressure \< 135/90
- Serum HbA1C \> 7%
- Serum creatinine \< 1mg%
- Urine microalbumin \< 300 mg/day
- Body mass index (BMI) \< 35 kg/m2
Exclusion
- Insulin-dependent diabetic patients
- Patient with persistent microalbuminuria
- Patient with history of severe hypertension
- Congestive heart failure
- Patient receiving renin-angiotensin-aldosterone system (RAAS)-related anti-hypertensive medications.
- Patient with major hepatic disease
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00192803
Last Update
February 23 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Internal Ward "A", Rambam Medical Center
Haifa, Israel